AS Grindeks: peers
AS Grindeks beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
AS Grindeks, As Olainfarm, Egetis Therapeutics AB (publ), Pihlajalinna Oyj, Photocure ASA, Tiziana Life Sciences Ltd, Adaptimmune Therapeutics, Xspray Pharma AB (publ): the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | AS Grindeksbase GRD1R.RG · 🇱🇻 LV Percentile in Healthcare Percentile in Latvia | As Olainfarm UU4.F · 🇱🇻 LV Percentile in Healthcare Percentile in Latvia | Egetis Therapeutics AB (publ) EGTX.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Pihlajalinna Oyj PIHLIS.HE · 🇫🇮 FI Percentile in Healthcare Percentile in Finland | Photocure ASA PHO.OL · 🇳🇴 NO Percentile in Healthcare Percentile in Norway | Tiziana Life Sciences Ltd TLSA · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Adaptimmune Therapeutics ADAP · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Xspray Pharma AB (publ) XSPRAY.ST · 🇸🇪 SE Percentile in Healthcare Percentile in Sweden | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $158 Mlast known, Jan 1, 2021 · Market dataLast known value: no current one5th of 8 | $124 Mlast known, Jan 1, 2021 · Market dataLast known value: no current one7th of 8 | $164 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8 | $174 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $172 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $144 MAug 1, 2026 · Market data6th of 8 | $200 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one1st of 8 | $121 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8 | $161 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $119 MFY2022 · Wikidata3rd of 6 | $6 MFY2025 · ESEF5th of 6 | $735 MFY2025 · ESEF1st of 6 | $51 MFY2025 · ESEF4th of 6 | —— | $178 MFY2024 · SEC2nd of 6 | $0 MFY2025 · ESEF6th of 6 | $85 M6 ranked |
| Net income (Higher is better) | —— | $19 MFY2022 · Wikidata2nd of 7 | $-35 MFY2025 · ESEF6th of 7 | $42 MFY2025 · ESEF1st of 7 | $-0 MFY2025 · ESEF3rd of 7 | $-12 MFY2024 · SEC4th of 7 | $-71 MFY2024 · SEC7th of 7 | $-17 MFY2025 · ESEF5th of 7 | $-12 M7 ranked |
| Employees (Better neither way: ranked highest first) | —— | 1,0542022 · Profile1st of 2 | —— | —— | —— | 3December 31, 2025 · Profile2nd of 2 | —— | —— | 5292 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | +45.6%FY2025 · ESEF2nd of 483rd97th | -3.5%FY2025 · ESEF4th of 419th20th | +4.8%FY2025 · ESEF3rd of 437th40th | ———— | +195.3%FY2024 · SEC1st of 496th99th | ———— | +25.2%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | +207.1%FY2024 · SEConly one with it99th99th | ———— | +207.1%— |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | +45.7%FY2025 · ESEFonly one with it75th81st | ———— | ———— | ———— | ———— | +45.7%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | 19.8%FY2025 · ESEF3rd of 39th21st | ———— | 92.1%FY2025 · ESEF2nd of 393rd96th | ———— | 100.0%FY2024 · SEC1st of 3100th100th | ———— | 92.1%3 ranked |
| Operating margin (Higher is better) | ———— | ———— | -545.0%FY2025 · ESEF4th of 46th0th | 8.1%FY2025 · ESEF1st of 470th61st | -0.1%FY2025 · ESEF2nd of 457th25th | ———— | -38.6%FY2024 · SEC3rd of 435th6th | ———— | -19.4%4 ranked |
| Net margin (Higher is better) | ———— | ———— | -549.1%FY2025 · ESEF4th of 44th0th | 5.8%FY2025 · ESEF1st of 471st66th | -0.3%FY2025 · ESEF2nd of 459th28th | ———— | -39.8%FY2024 · SEC3rd of 434th7th | ———— | -20.0%4 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | -430.6%FY2025 · ESEF3rd of 38th0th | ———— | 1.9%FY2025 · ESEF1st of 356th41st | ———— | -41.6%FY2024 · SEC2nd of 329th4th | ———— | -41.6%3 ranked |
| Return on equity (Higher is better) | ———— | ———— | -85.6%FY2025 · ESEF4th of 629th3rd | 21.1%FY2025 · ESEF1st of 691st85th | -0.3%FY2025 · ESEF2nd of 672nd27th | -250.2%FY2024 · SEC5th of 67th1st | -275.7%FY2024 · SEC6th of 66th0th | -28.6%FY2025 · ESEF3rd of 655th10th | -57.1%6 ranked |
| Valuation | |||||||||
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | 36.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | —— |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | -1.1%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | —— |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | 4.6×FY2024 · SEConly one with it94th95th | ———— | 4.6×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | 1 of 5FY2025 · Scorecard3rd of 6 | 4 of 5FY2025 · Scorecard1st of 6 | 1 of 5FY2025 · Scorecard3rd of 6 | 0 of 6FY2024 · Scorecard5th of 6 | 9 of 16FY2024 · Scorecard2nd of 6 | 0 of 3FY2025 · Scorecard5th of 6 | 20% passed6 ranked |
| Growth checks (Higher is better) | —— | —— | 1 of 2FY2025 · Scorecard2nd of 6 | 1 of 2FY2025 · Scorecard2nd of 6 | 1 of 2FY2025 · Scorecard2nd of 6 | 0 of 2FY2024 · Scorecard5th of 6 | 5 of 6FY2024 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard5th of 6 | 50% passed6 ranked |
| Profitability checks (Higher is better) | —— | —— | 0 of 3FY2025 · Scorecard3rd of 6 | 3 of 3FY2025 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard3rd of 6 | 0 of 3FY2024 · Scorecard3rd of 6 | 2 of 5FY2024 · Scorecard2nd of 6 | 0 of 2FY2025 · Scorecard3rd of 6 | 0% passed6 ranked |
| Financial health checks (Higher is better) | —— | —— | —— | —— | —— | 0 of 1FY2024 · Scorecard2nd of 2 | 2 of 4FY2024 · Scorecard1st of 2 | —— | 25% passed2 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | —— | —— | —— | 0 of 1FY2024 · Scorecardonly one with it | —— | 0% passed— |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | 2.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | —— | —— | 2.8%— |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | 362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | —— | —— | 36— |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | -1.0 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | —— | —— | -1.0 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = AS Grindeks: How market caps are worked out; As Olainfarm: How market caps are worked out; Egetis Therapeutics AB (publ): How market caps are worked out; Pihlajalinna Oyj: How market caps are worked out; Photocure ASA: How market caps are worked out; Tiziana Life Sciences Ltd: How market caps are worked out; Adaptimmune Therapeutics: How market caps are worked out; Xspray Pharma AB (publ): How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| AS Grindeks | — | — | — |
| As Olainfarm | — | — | — |
| Egetis Therapeutics AB (publ) | -545.0%FY2025 | 6th percentile in Healthcaremedian -7.7%, 674 companies | 0th percentile in Swedenmedian 8.0%, 128 companies |
| Pihlajalinna Oyj | 8.1%FY2025 | 70th percentile in Healthcaremedian -7.7%, 674 companies | 61st percentile in Finlandmedian 4.9%, 99 companies |
| Photocure ASA | -0.1%FY2025 | 57th percentile in Healthcaremedian -7.7%, 674 companies | 25th percentile in Norwaymedian 6.0%, 95 companies |
| Tiziana Life Sciences Ltd | — | — | — |
| Adaptimmune Therapeutics | -38.6%FY2024 | 35th percentile in Healthcaremedian -7.7%, 674 companies | 6th percentile in UKmedian 8.5%, 313 companies |
| Xspray Pharma AB (publ) | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | AS Grindeks | As Olainfarm | Egetis Therapeutics AB (publ) | Pihlajalinna Oyj | Photocure ASA | Tiziana Life Sciences Ltd | Adaptimmune Therapeutics | Xspray Pharma AB (publ) |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | $6 MESEF3rd | $735 MESEF1st | $51 MESEF2nd | — | — | $0 MESEF4th |
| 2024 | — | — | $4 MESEF4th | $762 MESEF1st | $49 MESEF3rd | — | $178 MSEC2nd | $0 MESEF5th |
| 2023 | — | — | — | — | — | — | $60 MSEC | — |
| 2022 | — | $119 MWD1st | — | — | — | — | $27 MSEC2nd | — |
| 2021 | — | — | — | — | — | — | $6 MSEC | — |
| 2020 | — | — | — | — | — | — | $4 MSEC | — |
| 2019 | — | — | — | — | — | — | $1 MSEC | — |
| 2018 | — | — | — | — | — | — | $60 MSEC | — |
| 2017 | — | — | — | — | — | — | $38 MSEC | — |
| 2016 | — | — | — | — | — | — | $14 MSEC | — |
| 2015 | — | — | — | — | — | — | $10 MSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of AS Grindeks#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- As OlainfarmUU4.F · 🇱🇻 LatviaSame sector: Healthcare (Pharmaceutical) · Similar size: $124 M market cap against $158 M · Same country: LatviaMarket cap $124 M (last known, Jan 1, 2021) · revenue $119 M (fiscal 2022)68 of 100 (industry or sector 25 + size 28 + country 15)In the group
- Egetis Therapeutics AB (publ)EGTX.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $164 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $164 M (last known, Jan 5, 2024) · revenue $6 M (year to December 2025)67 of 100 (industry or sector 25 + size 30 + country 7 + figures on file 5)In the group
- Pihlajalinna OyjPIHLIS.HE · 🇫🇮 FinlandSame sector: Healthcare (Medical Care Facilities) · Similar size: $174 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $174 M (last known, Jan 5, 2024) · revenue $735 M (year to December 2025)66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)In the group
- Photocure ASAPHO.OL · 🇳🇴 NorwaySame sector: Healthcare (Pharmaceutical) · Similar size: $172 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $172 M (last known, Jan 5, 2024) · revenue $51 M (year to December 2025)66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)In the group
- Tiziana Life Sciences LtdTLSA · 🇬🇧 UKSame sector: Healthcare (Biotechnology) · Similar size: $144 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $144 M (Aug 1, 2026)66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)In the group
- Adaptimmune TherapeuticsADAP · 🇬🇧 UKSame sector: Healthcare (Biotechnology) · Similar size: $200 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $200 M (last known, Jan 5, 2024) · revenue $178 M (year to December 2024)66 of 100 (industry or sector 25 + size 29 + country 7 + figures on file 5)In the group
- Xspray Pharma AB (publ)XSPRAY.ST · 🇸🇪 SwedenSame sector: Healthcare (Biotechnology) · Similar size: $121 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $121 M (last known, Jan 5, 2024) · revenue $0 M (year to December 2025)65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)In the group
- ArcticZymes Technologies ASAAZT.OL · 🇳🇴 NorwaySame sector: Healthcare (Biotechnology) · Similar size: $207 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $207 M (last known, Jan 5, 2024) · revenue $11 M (year to December 2025)65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)+ Add
- BioPorto A/SBIOPOR.CO · 🇩🇰 DenmarkSame sector: Healthcare (Diagnostics and Research) · Similar size: $118 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $118 M (last known, Jan 5, 2024)65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)+ Add
- Sedana Medical AB (publ)SEDANA.ST · 🇸🇪 SwedenSame sector: Healthcare (Medical Instruments) · Similar size: $223 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $223 M (last known, Jan 5, 2024) · revenue $20 M (year to December 2025)65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)+ Add
- Oriola OyjOKDAV.HE · 🇫🇮 FinlandSame sector: Healthcare (Retail - Pharmacy) · Similar size: $221 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $221 M (last known, Jan 5, 2024) · revenue $2.1 B (year to December 2025)65 of 100 (industry or sector 25 + size 28 + country 7 + figures on file 5)+ Add
- OneMedNet CorpONMD · 🇬🇧 UKSame sector: Healthcare (Diagnostics and Research) · Similar size: $237 M market cap against $158 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $237 M (Oct 14, 2026) · revenue $1 M (year to December 2025)64 of 100 (industry or sector 25 + size 27 + country 7 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.